bmpr2 Search Results


91
Addgene inc bmpr2 coding sequence
Figure 1. The BMP pathway in the colon. BMP2 and BMP4 are the most abundant ligands of the BMP pathway in the bowel mucosa. They are able to bind the <t>BMPR1A-BMPR2</t> complex on the surface of colonocytes, therefore, triggering R-SMAD phosphorylation and downstream gene regulation in the canonical pathway. In addition, BMP can also mediate proliferation by convergent pathways, such as ERK, JNK, and p38. Created with BioRender.com.
Bmpr2 Coding Sequence, supplied by Addgene inc, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bmpr2/pHAGE-BMPR2+(Plasmid+%23116718)/pm36907526-70-8-13
Average 91 stars, based on 1 article reviews
bmpr2 coding sequence - by Bioz Stars, 2026-11
91/100 stars
  Buy from Supplier

93
Proteintech bmpr2
Immunohistochemical localization of ACVR1 ( a,b,c ) and <t>BMPR2</t> ( d,e,f ) receptors in rat jejunum. e ) The arrows show strong immunostaining in the lamina propria; the asterisk designates the longitudinal muscularis layer. To determine the localization of BMP receptors, we performed immunohistochemical staining on jejunum sections from 6 different rats. Sections were examined by light microscopy (Leica DM 2000) using 20x and 40x objectives. Representative images are shown. Scale bars: 50 μm.
Bmpr2, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bmpr2/BMPR2+Antibody/pmc12421720-18-0-4
Average 93 stars, based on 1 article reviews
bmpr2 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

94
ABclonal Biotechnology bone morphogenetic protein receptor 2 bmpr2
Fig. 1. Effects of maternal mulberry-leaf flavonoids (MLF) supplementation on the relative mRNA expression and protein abundance in the breast muscle of offspring embryo at 13 d. (A) Relative mRNA expression of genes related with myogenic regulatory factors (n ¼ 8). (B to F) Western blot analysis of p-MAPK, MAPK, p-Smad1/5/9, Smad1, BMP2, <t>BMPR2,</t> MSTN and Myf5 in the breast muscle (n ¼ 4). ERa ¼ estrogen receptor alpha; ERb ¼ estrogen receptor beta; Pax7 ¼ paired box protein pax-7; MSTN ¼ myostatin; Myf5 ¼ myogenic factor 5; MyoD ¼ myogenic differentiation antigen; MyoG ¼ myogenin; MAPK ¼ mitogen-activated protein kinase; p-MAPK ¼ phospho-mitogen-activated protein kinase; Smad1 ¼ SMAD family member 1; p-Smad1/5/9 ¼ phospho-SMAD family member 1/5/9; BMP2 ¼ bone morphogenetic protein 2; BMPR2 ¼ bone morphogenetic protein receptor 2; GAPDH ¼ glyceraldehyde-3-phosphate dehydrogenase. CON, the offspring embryos of breeder hens fed with a normal diet; L-MLF, the offspring embryos of breeder hens fed a basal diet supplemented with 30 mg/kg MLF; H-MLF, the offspring embryos of breeder hens fed a basal diet supplemented with 60 mg/kg MLF. a,bDifferent letter represents statistically significant differences among the groups (P < 0.05).
Bone Morphogenetic Protein Receptor 2 Bmpr2, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bmpr2/BMPR2+Rabbit+pAb/pm39035983-109-53-67
Average 94 stars, based on 1 article reviews
bone morphogenetic protein receptor 2 bmpr2 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

93
OriGene sirna against bmpr2
Calcitriol inhibits PASMC proliferation via <t>BMPR2.</t> Human control PASMC were transfected with siRNA for BMPR2 (siBMPR2) or control siRNA (scramble). ( A ) BMPR2 mRNA expression assessed by qRT-PCR after 48 h post-transfection. Data is expressed as scatter plots and bars with medians, * p < 0.05, Mann–Whitney test. ( B ) Effects of calcitriol on proliferation in silenced BMPR2 PASMC measured by MTT assay. Results are expressed as mean ± SEM. *p < 0.05, t-test vs scramble. ( C ) and ( D ) Effects of calcitriol (1–100 nmol/l) on proliferation in PASMC transfected with siBMPR2 or scramble, measured by MTT and BrdU assays, respectively. * p < 0.05, two-way ANOVA, Bonferroni post hoc test, vs scramble. ( E ) Effects of calcitriol on proliferation in PASMC in the presence or absence of DMH1 (5 µmol/l), by MTT and BrdU assay; *** p < 0.001 calcitriol vs vehicle (black column), two way-ANOVA. n = 4–5 different cultures in duplicate or triplicate.
Sirna Against Bmpr2, supplied by OriGene, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bmpr2/BMPR2+Human+siRNA+Oligo+Duplex/pmc11551162-187-7-11
Average 93 stars, based on 1 article reviews
sirna against bmpr2 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

90
OriGene anti bmprii rabbit pigg
Calcitriol inhibits PASMC proliferation via <t>BMPR2.</t> Human control PASMC were transfected with siRNA for BMPR2 (siBMPR2) or control siRNA (scramble). ( A ) BMPR2 mRNA expression assessed by qRT-PCR after 48 h post-transfection. Data is expressed as scatter plots and bars with medians, * p < 0.05, Mann–Whitney test. ( B ) Effects of calcitriol on proliferation in silenced BMPR2 PASMC measured by MTT assay. Results are expressed as mean ± SEM. *p < 0.05, t-test vs scramble. ( C ) and ( D ) Effects of calcitriol (1–100 nmol/l) on proliferation in PASMC transfected with siBMPR2 or scramble, measured by MTT and BrdU assays, respectively. * p < 0.05, two-way ANOVA, Bonferroni post hoc test, vs scramble. ( E ) Effects of calcitriol on proliferation in PASMC in the presence or absence of DMH1 (5 µmol/l), by MTT and BrdU assay; *** p < 0.001 calcitriol vs vehicle (black column), two way-ANOVA. n = 4–5 different cultures in duplicate or triplicate.
Anti Bmprii Rabbit Pigg, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bmpr2/BMPR2+(N-term)+Rabbit+Polyclonal+Antibody/pmc08620704-168-53-57
Average 90 stars, based on 1 article reviews
anti bmprii rabbit pigg - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

93
OriGene targetplus bmpr2 origene
Calcitriol inhibits PASMC proliferation via <t>BMPR2.</t> Human control PASMC were transfected with siRNA for BMPR2 (siBMPR2) or control siRNA (scramble). ( A ) BMPR2 mRNA expression assessed by qRT-PCR after 48 h post-transfection. Data is expressed as scatter plots and bars with medians, * p < 0.05, Mann–Whitney test. ( B ) Effects of calcitriol on proliferation in silenced BMPR2 PASMC measured by MTT assay. Results are expressed as mean ± SEM. *p < 0.05, t-test vs scramble. ( C ) and ( D ) Effects of calcitriol (1–100 nmol/l) on proliferation in PASMC transfected with siBMPR2 or scramble, measured by MTT and BrdU assays, respectively. * p < 0.05, two-way ANOVA, Bonferroni post hoc test, vs scramble. ( E ) Effects of calcitriol on proliferation in PASMC in the presence or absence of DMH1 (5 µmol/l), by MTT and BrdU assay; *** p < 0.001 calcitriol vs vehicle (black column), two way-ANOVA. n = 4–5 different cultures in duplicate or triplicate.
Targetplus Bmpr2 Origene, supplied by OriGene, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bmpr2/BMPR2+(NM_001204)+Human+Tagged+ORF+Clone/pmc11998417__12931_2025_3182_MOESM2_ESM-5-47-49
Average 93 stars, based on 1 article reviews
targetplus bmpr2 origene - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

90
Elabscience Biotechnology human bone morphogenetic protein receptor type 2 elisa kit
Calcitriol inhibits PASMC proliferation via <t>BMPR2.</t> Human control PASMC were transfected with siRNA for BMPR2 (siBMPR2) or control siRNA (scramble). ( A ) BMPR2 mRNA expression assessed by qRT-PCR after 48 h post-transfection. Data is expressed as scatter plots and bars with medians, * p < 0.05, Mann–Whitney test. ( B ) Effects of calcitriol on proliferation in silenced BMPR2 PASMC measured by MTT assay. Results are expressed as mean ± SEM. *p < 0.05, t-test vs scramble. ( C ) and ( D ) Effects of calcitriol (1–100 nmol/l) on proliferation in PASMC transfected with siBMPR2 or scramble, measured by MTT and BrdU assays, respectively. * p < 0.05, two-way ANOVA, Bonferroni post hoc test, vs scramble. ( E ) Effects of calcitriol on proliferation in PASMC in the presence or absence of DMH1 (5 µmol/l), by MTT and BrdU assay; *** p < 0.001 calcitriol vs vehicle (black column), two way-ANOVA. n = 4–5 different cultures in duplicate or triplicate.
Human Bone Morphogenetic Protein Receptor Type 2 Elisa Kit, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bmpr2/Human+BMPR2+(Bone+Morphogenetic+Protein+Receptor+%E2%85%A1)+ELISA+Kit/10__37275_slash_bsm__v10i5__1582-99-2-19
Average 90 stars, based on 1 article reviews
human bone morphogenetic protein receptor type 2 elisa kit - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

98
Thermo Fisher gene exp bmpr2 hs00176148 m1
Calcitriol inhibits PASMC proliferation via <t>BMPR2.</t> Human control PASMC were transfected with siRNA for BMPR2 (siBMPR2) or control siRNA (scramble). ( A ) BMPR2 mRNA expression assessed by qRT-PCR after 48 h post-transfection. Data is expressed as scatter plots and bars with medians, * p < 0.05, Mann–Whitney test. ( B ) Effects of calcitriol on proliferation in silenced BMPR2 PASMC measured by MTT assay. Results are expressed as mean ± SEM. *p < 0.05, t-test vs scramble. ( C ) and ( D ) Effects of calcitriol (1–100 nmol/l) on proliferation in PASMC transfected with siBMPR2 or scramble, measured by MTT and BrdU assays, respectively. * p < 0.05, two-way ANOVA, Bonferroni post hoc test, vs scramble. ( E ) Effects of calcitriol on proliferation in PASMC in the presence or absence of DMH1 (5 µmol/l), by MTT and BrdU assay; *** p < 0.001 calcitriol vs vehicle (black column), two way-ANOVA. n = 4–5 different cultures in duplicate or triplicate.
Gene Exp Bmpr2 Hs00176148 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bmpr2/Gene+Exp%2E+BMPR2%2C+Hs00176148_m1/us12600952-125-59-62
Average 98 stars, based on 1 article reviews
gene exp bmpr2 hs00176148 m1 - by Bioz Stars, 2026-11
98/100 stars
  Buy from Supplier

93
Biorbyt bmpr2
Structural details of inhibitor binding to SMURF1, conservation of lysine residues on α helix #1, and AlphaFold model of the <t>SMURF1:BMPR2</t> complex, related to , , , and (A) Crystallography parameters. ∗ The highest resolution shell is shown in parenthesis. (B) Surface representation of SMURF1 shows that the inhibitor is minimally exposed. (C) Detailed structural insight into the SMURF1—inhibitor complex, with a zoomed view of the binding cavity from three different angles. (D) 2D representation of the inhibitor binding site, rendered using LigPlot+ v.2.2 https://www.ebi.ac.uk/thornton-srv/software/LigPlus/ . (E) mFo-DFc simulated-annealing electron density omit map showing the α10 and the hinge region without (left) and with (right) the inhibitor. The map was calculated by omitting the entire model of the α 10, the hinge, and the inhibitor using simulated-annealing sigma A analysis contoured at 2.75 (SMURF1, apo) and 2.05 Å (SMURF1, Cpd-8) at 3σ. (F) Structures of HECT ligase showing conservation of lysine residues on α helix #1. Superimposing the structures of Rsp5 (3OLM), NEDD4 (2XBB), and SMURF1 and AlphaFold model of E6AP/UBE3A HECT domains shows the conservation of lysine (K) residues on α helix #1, previously demonstrated to undergo self-ubiquitylation that downregulates the ligase activity. (G) AlphaFold model of the SMURF1:BMPR2 complex. The sequences of full-length SMURF1 and the intracellular domain of BMPR2 were modeled in AlphaFold3. The domains of SMURF1 are indicated. Residues predicted to participate in binding are shown as ball-and-sticks. The model suggests that WW1 and WW2 domains directly interact with the kinase domain of BMPR2.
Bmpr2, supplied by Biorbyt, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bmpr2/BMPR2+antibody/pmc12087876-549-24-26
Average 93 stars, based on 1 article reviews
bmpr2 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

93
Addgene inc mir sensor assay
Structural details of inhibitor binding to SMURF1, conservation of lysine residues on α helix #1, and AlphaFold model of the <t>SMURF1:BMPR2</t> complex, related to , , , and (A) Crystallography parameters. ∗ The highest resolution shell is shown in parenthesis. (B) Surface representation of SMURF1 shows that the inhibitor is minimally exposed. (C) Detailed structural insight into the SMURF1—inhibitor complex, with a zoomed view of the binding cavity from three different angles. (D) 2D representation of the inhibitor binding site, rendered using LigPlot+ v.2.2 https://www.ebi.ac.uk/thornton-srv/software/LigPlus/ . (E) mFo-DFc simulated-annealing electron density omit map showing the α10 and the hinge region without (left) and with (right) the inhibitor. The map was calculated by omitting the entire model of the α 10, the hinge, and the inhibitor using simulated-annealing sigma A analysis contoured at 2.75 (SMURF1, apo) and 2.05 Å (SMURF1, Cpd-8) at 3σ. (F) Structures of HECT ligase showing conservation of lysine residues on α helix #1. Superimposing the structures of Rsp5 (3OLM), NEDD4 (2XBB), and SMURF1 and AlphaFold model of E6AP/UBE3A HECT domains shows the conservation of lysine (K) residues on α helix #1, previously demonstrated to undergo self-ubiquitylation that downregulates the ligase activity. (G) AlphaFold model of the SMURF1:BMPR2 complex. The sequences of full-length SMURF1 and the intracellular domain of BMPR2 were modeled in AlphaFold3. The domains of SMURF1 are indicated. Residues predicted to participate in binding are shown as ball-and-sticks. The model suggests that WW1 and WW2 domains directly interact with the kinase domain of BMPR2.
Mir Sensor Assay, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bmpr2/pmirGLO-Bmpr2-1719+(Plasmid+%2349379)/bio_rxiv__2025__11__21__689335-78-11-18
Average 93 stars, based on 1 article reviews
mir sensor assay - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

90
RayBiotech inc bmprii
FIGURE 3 | Urine proteins that correlate best with urine creatinine. The aptamer-based screen identified five urine proteins that correlated best with urine creatinine but not differ between subject groups. As described in Figure 1, the levels of 1129 urine proteins were assayed in 7 active LN, 8 inactive LN, 8 healthy controls using an aptamer-based proteomic screen. Of these, urine <t>BMPRII,</t> <t>Dectin-1,</t> <t>HVEM,</t> RELT, and SPINT2 (A–E) exhibited the highest Pearson R correlation with creatinine but did not differ significantly between the subject groups.
Bmprii, supplied by RayBiotech inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bmpr2/Human+BMPR-II+ELISA/pm35774777-62-14-18
Average 90 stars, based on 1 article reviews
bmprii - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

91
Addgene inc pmirglo plasmid
FIGURE 3 | Urine proteins that correlate best with urine creatinine. The aptamer-based screen identified five urine proteins that correlated best with urine creatinine but not differ between subject groups. As described in Figure 1, the levels of 1129 urine proteins were assayed in 7 active LN, 8 inactive LN, 8 healthy controls using an aptamer-based proteomic screen. Of these, urine <t>BMPRII,</t> <t>Dectin-1,</t> <t>HVEM,</t> RELT, and SPINT2 (A–E) exhibited the highest Pearson R correlation with creatinine but did not differ significantly between the subject groups.
Pmirglo Plasmid, supplied by Addgene inc, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bmpr2/pmirGLO-Bmpr2-%CE%9417+(Plasmid+%2349380)/pmc06945089-118-48-51
Average 91 stars, based on 1 article reviews
pmirglo plasmid - by Bioz Stars, 2026-11
91/100 stars
  Buy from Supplier

Image Search Results


Figure 1. The BMP pathway in the colon. BMP2 and BMP4 are the most abundant ligands of the BMP pathway in the bowel mucosa. They are able to bind the BMPR1A-BMPR2 complex on the surface of colonocytes, therefore, triggering R-SMAD phosphorylation and downstream gene regulation in the canonical pathway. In addition, BMP can also mediate proliferation by convergent pathways, such as ERK, JNK, and p38. Created with BioRender.com.

Journal: Gastroenterology

Article Title: BMPR2 as a Novel Predisposition Gene for Hereditary Colorectal Polyposis.

doi: 10.1053/j.gastro.2023.03.006

Figure Lengend Snippet: Figure 1. The BMP pathway in the colon. BMP2 and BMP4 are the most abundant ligands of the BMP pathway in the bowel mucosa. They are able to bind the BMPR1A-BMPR2 complex on the surface of colonocytes, therefore, triggering R-SMAD phosphorylation and downstream gene regulation in the canonical pathway. In addition, BMP can also mediate proliferation by convergent pathways, such as ERK, JNK, and p38. Created with BioRender.com.

Article Snippet: The identified BMPR2 variants were introduced into the BMPR2 coding sequence (no. 116718, Addgene) by a simple 1- step PCR amplification with nonoverlapping primers (Q5 SiteDirected Mutagenesis Kit, New England Biolabs, Ipswich, MA).

Techniques: Phospho-proteomics

Figure 2. BMPR2 variants drive a proliferative response and impair the BMP4-mediated growth inhibition. Characterization of the proliferative capacity of 2 different BMPR2 clones (B26 and B31) in which the 3 BMPR2 variants were reintroduced. (A) MTS cell proliferation assay. Samples were assayed in triplicate and the experiment was repeated 5 times (n ¼ 5). (B) Plating efficiency (colonies originated from single cells) in the colony-formation assay. Samples were assayed in duplicate and the experiment was repeated 3 times (n ¼ 3). (C) MTS cell proliferation assay in the presence or absence of 50 ng/mL of BMP4. Data are represented as the growth difference between treated and untreated cells. Samples were assayed in triplicate and the experiment was repeated 4 times (n ¼ 4). Data represent mean ± SD. *P < .05, **P < .01, ***P < .001 for the analysis of variance with the least significant difference post-hoc test.

Journal: Gastroenterology

Article Title: BMPR2 as a Novel Predisposition Gene for Hereditary Colorectal Polyposis.

doi: 10.1053/j.gastro.2023.03.006

Figure Lengend Snippet: Figure 2. BMPR2 variants drive a proliferative response and impair the BMP4-mediated growth inhibition. Characterization of the proliferative capacity of 2 different BMPR2 clones (B26 and B31) in which the 3 BMPR2 variants were reintroduced. (A) MTS cell proliferation assay. Samples were assayed in triplicate and the experiment was repeated 5 times (n ¼ 5). (B) Plating efficiency (colonies originated from single cells) in the colony-formation assay. Samples were assayed in duplicate and the experiment was repeated 3 times (n ¼ 3). (C) MTS cell proliferation assay in the presence or absence of 50 ng/mL of BMP4. Data are represented as the growth difference between treated and untreated cells. Samples were assayed in triplicate and the experiment was repeated 4 times (n ¼ 4). Data represent mean ± SD. *P < .05, **P < .01, ***P < .001 for the analysis of variance with the least significant difference post-hoc test.

Article Snippet: The identified BMPR2 variants were introduced into the BMPR2 coding sequence (no. 116718, Addgene) by a simple 1- step PCR amplification with nonoverlapping primers (Q5 SiteDirected Mutagenesis Kit, New England Biolabs, Ipswich, MA).

Techniques: Inhibition, Clone Assay, Proliferation Assay, Colony Assay

Figure 3. BMPR2 variants act through SMAD or non-SMAD effectors, depending on their position. Characterization of the SMAD1/5/8 pathway activity of 2 different BMPR2 clones (B26 and B31) in which the 3 BMPR2 variants were reintroduced. (A) Quantitative analysis of the phosphorylated levels of SMAD1 (Ser463/465) by means of enzyme-linked immunosorbent assay in the presence or absence of 50 ng/mL of BMP4. Samples were assayed in duplicate and the experiment was repeated 3 times (n ¼ 3). (B) Real-time PCR quantification of ID1 and ID3 expression levels, 2 canonical BMP-SMAD downstream targets, in clone B26. Samples were assayed in triplicate and the experiment was repeated 3 times (n ¼ 3). Data represent mean ± SD. *P < .05, **P < .01, ***P < .001 for the analysis of variance with the least significant difference post-hoc test.

Journal: Gastroenterology

Article Title: BMPR2 as a Novel Predisposition Gene for Hereditary Colorectal Polyposis.

doi: 10.1053/j.gastro.2023.03.006

Figure Lengend Snippet: Figure 3. BMPR2 variants act through SMAD or non-SMAD effectors, depending on their position. Characterization of the SMAD1/5/8 pathway activity of 2 different BMPR2 clones (B26 and B31) in which the 3 BMPR2 variants were reintroduced. (A) Quantitative analysis of the phosphorylated levels of SMAD1 (Ser463/465) by means of enzyme-linked immunosorbent assay in the presence or absence of 50 ng/mL of BMP4. Samples were assayed in duplicate and the experiment was repeated 3 times (n ¼ 3). (B) Real-time PCR quantification of ID1 and ID3 expression levels, 2 canonical BMP-SMAD downstream targets, in clone B26. Samples were assayed in triplicate and the experiment was repeated 3 times (n ¼ 3). Data represent mean ± SD. *P < .05, **P < .01, ***P < .001 for the analysis of variance with the least significant difference post-hoc test.

Article Snippet: The identified BMPR2 variants were introduced into the BMPR2 coding sequence (no. 116718, Addgene) by a simple 1- step PCR amplification with nonoverlapping primers (Q5 SiteDirected Mutagenesis Kit, New England Biolabs, Ipswich, MA).

Techniques: Activity Assay, Clone Assay, Enzyme-linked Immunosorbent Assay, Real-time Polymerase Chain Reaction, Expressing

Immunohistochemical localization of ACVR1 ( a,b,c ) and BMPR2 ( d,e,f ) receptors in rat jejunum. e ) The arrows show strong immunostaining in the lamina propria; the asterisk designates the longitudinal muscularis layer. To determine the localization of BMP receptors, we performed immunohistochemical staining on jejunum sections from 6 different rats. Sections were examined by light microscopy (Leica DM 2000) using 20x and 40x objectives. Representative images are shown. Scale bars: 50 μm.

Journal: European Journal of Histochemistry : EJH

Article Title: Expression of bone morphogenetic protein signaling pathway players in the jejunum and colon of adult rats

doi: 10.4081/ejh.2025.4174

Figure Lengend Snippet: Immunohistochemical localization of ACVR1 ( a,b,c ) and BMPR2 ( d,e,f ) receptors in rat jejunum. e ) The arrows show strong immunostaining in the lamina propria; the asterisk designates the longitudinal muscularis layer. To determine the localization of BMP receptors, we performed immunohistochemical staining on jejunum sections from 6 different rats. Sections were examined by light microscopy (Leica DM 2000) using 20x and 40x objectives. Representative images are shown. Scale bars: 50 μm.

Article Snippet: BMPR2 , 1:100 , ProteinTech - 19087-1 - AP.

Techniques: Immunohistochemical staining, Immunostaining, Staining, Light Microscopy

Immunohistochemical localization of ACVR1 ( a,b,c ) and BMPR2 ( d,e,f ) receptors in rat colon. b ) The asterisk shows surface colonocytes. To determine the localization of BMP receptors, we performed immunohistochemical staining on colon sections from 6 different rats. Sections were examined by light microscopy (Leica DM 2000) using 20x and 40x objectives. Representative images are shown. Scale bars: 50 μm.

Journal: European Journal of Histochemistry : EJH

Article Title: Expression of bone morphogenetic protein signaling pathway players in the jejunum and colon of adult rats

doi: 10.4081/ejh.2025.4174

Figure Lengend Snippet: Immunohistochemical localization of ACVR1 ( a,b,c ) and BMPR2 ( d,e,f ) receptors in rat colon. b ) The asterisk shows surface colonocytes. To determine the localization of BMP receptors, we performed immunohistochemical staining on colon sections from 6 different rats. Sections were examined by light microscopy (Leica DM 2000) using 20x and 40x objectives. Representative images are shown. Scale bars: 50 μm.

Article Snippet: BMPR2 , 1:100 , ProteinTech - 19087-1 - AP.

Techniques: Immunohistochemical staining, Staining, Light Microscopy

Fig. 1. Effects of maternal mulberry-leaf flavonoids (MLF) supplementation on the relative mRNA expression and protein abundance in the breast muscle of offspring embryo at 13 d. (A) Relative mRNA expression of genes related with myogenic regulatory factors (n ¼ 8). (B to F) Western blot analysis of p-MAPK, MAPK, p-Smad1/5/9, Smad1, BMP2, BMPR2, MSTN and Myf5 in the breast muscle (n ¼ 4). ERa ¼ estrogen receptor alpha; ERb ¼ estrogen receptor beta; Pax7 ¼ paired box protein pax-7; MSTN ¼ myostatin; Myf5 ¼ myogenic factor 5; MyoD ¼ myogenic differentiation antigen; MyoG ¼ myogenin; MAPK ¼ mitogen-activated protein kinase; p-MAPK ¼ phospho-mitogen-activated protein kinase; Smad1 ¼ SMAD family member 1; p-Smad1/5/9 ¼ phospho-SMAD family member 1/5/9; BMP2 ¼ bone morphogenetic protein 2; BMPR2 ¼ bone morphogenetic protein receptor 2; GAPDH ¼ glyceraldehyde-3-phosphate dehydrogenase. CON, the offspring embryos of breeder hens fed with a normal diet; L-MLF, the offspring embryos of breeder hens fed a basal diet supplemented with 30 mg/kg MLF; H-MLF, the offspring embryos of breeder hens fed a basal diet supplemented with 60 mg/kg MLF. a,bDifferent letter represents statistically significant differences among the groups (P < 0.05).

Journal: Animal nutrition (Zhongguo xu mu shou yi xue hui)

Article Title: Maternal supplementation with mulberry-leaf flavonoids improves the development of skeletal muscle in the offspring of chickens.

doi: 10.1016/j.aninu.2024.04.005

Figure Lengend Snippet: Fig. 1. Effects of maternal mulberry-leaf flavonoids (MLF) supplementation on the relative mRNA expression and protein abundance in the breast muscle of offspring embryo at 13 d. (A) Relative mRNA expression of genes related with myogenic regulatory factors (n ¼ 8). (B to F) Western blot analysis of p-MAPK, MAPK, p-Smad1/5/9, Smad1, BMP2, BMPR2, MSTN and Myf5 in the breast muscle (n ¼ 4). ERa ¼ estrogen receptor alpha; ERb ¼ estrogen receptor beta; Pax7 ¼ paired box protein pax-7; MSTN ¼ myostatin; Myf5 ¼ myogenic factor 5; MyoD ¼ myogenic differentiation antigen; MyoG ¼ myogenin; MAPK ¼ mitogen-activated protein kinase; p-MAPK ¼ phospho-mitogen-activated protein kinase; Smad1 ¼ SMAD family member 1; p-Smad1/5/9 ¼ phospho-SMAD family member 1/5/9; BMP2 ¼ bone morphogenetic protein 2; BMPR2 ¼ bone morphogenetic protein receptor 2; GAPDH ¼ glyceraldehyde-3-phosphate dehydrogenase. CON, the offspring embryos of breeder hens fed with a normal diet; L-MLF, the offspring embryos of breeder hens fed a basal diet supplemented with 30 mg/kg MLF; H-MLF, the offspring embryos of breeder hens fed a basal diet supplemented with 60 mg/kg MLF. a,bDifferent letter represents statistically significant differences among the groups (P < 0.05).

Article Snippet: After washing 4 times with TBST buffer, the membraneswere incubated overnight at 4 Cwith the following primary antibodies respectively: SMAD family member 1 (Smad1), phospho-SMAD family member 1/5/9 (p-Smad1/5/9) (AF6451 and AF8313; Affinity Biosciences, USA); phospho-mitogen-activated protein kinase (p-MAPK), myogenic factor 5 (Myf5), myostatin (MSTN), mTOR, phosphorylated mammalian target of rapamycin (p-mTOR), BMP2, bone morphogenetic protein receptor 2 (BMPR2) (AP1165, A16227, A6913, A2445, AP0094, A0231 and A5666; ABclonal Technology, Wuhan, China); and MAPK (8690S, Cell Signaling Technology, Boston, USA).

Techniques: Expressing, Quantitative Proteomics, Western Blot, Cell Characterization

Fig. 2. Effects of maternal mulberry-leaf flavonoids (MLF) supplementation on the relative mRNA expression and protein abundance in the breast muscle of offspring embryo at 19 d. (A) Relative mRNA expression of genes related with myogenic regulatory factors (n ¼ 8). (B to F) Western blot analysis of p-MAPK, MAPK, p-Smad1/5/9, Smad1, BMP2, BMPR2, MSTN and Myf5 in the breast muscle (n ¼ 4). ERa ¼ estrogen receptor alpha; ERb ¼ estrogen receptor beta; Pax7 ¼ paired box protein pax-7; MSTN ¼ myostatin; Myf5 ¼ myogenic factor 5; MyoD ¼ myogenic differentiation antigen; MyoG ¼ myogenin; MAPK ¼ mitogen-activated protein kinase; p-MAPK ¼ phospho-mitogen-activated protein kinase; Smad1 ¼ SMAD family member 1; p-Smad1/5/9 ¼ phospho-SMAD family member 1/5/9; BMP2 ¼ bone morphogenetic protein 2; BMPR2 ¼ bone morphogenetic protein receptor 2; GAPDH ¼ glyceraldehyde-3-phosphate dehydrogenase. CON, the offspring embryos of breeder hens fed with a normal diet; L-MLF, the offspring embryos of breeder hens fed a basal diet supplemented with 30 mg/kg MLF; H-MLF, the offspring embryos of breeder hens fed a basal diet supplemented with 60 mg/kg MLF. a,bDifferent letter represents statistically significant differences among the groups (P < 0.05).

Journal: Animal nutrition (Zhongguo xu mu shou yi xue hui)

Article Title: Maternal supplementation with mulberry-leaf flavonoids improves the development of skeletal muscle in the offspring of chickens.

doi: 10.1016/j.aninu.2024.04.005

Figure Lengend Snippet: Fig. 2. Effects of maternal mulberry-leaf flavonoids (MLF) supplementation on the relative mRNA expression and protein abundance in the breast muscle of offspring embryo at 19 d. (A) Relative mRNA expression of genes related with myogenic regulatory factors (n ¼ 8). (B to F) Western blot analysis of p-MAPK, MAPK, p-Smad1/5/9, Smad1, BMP2, BMPR2, MSTN and Myf5 in the breast muscle (n ¼ 4). ERa ¼ estrogen receptor alpha; ERb ¼ estrogen receptor beta; Pax7 ¼ paired box protein pax-7; MSTN ¼ myostatin; Myf5 ¼ myogenic factor 5; MyoD ¼ myogenic differentiation antigen; MyoG ¼ myogenin; MAPK ¼ mitogen-activated protein kinase; p-MAPK ¼ phospho-mitogen-activated protein kinase; Smad1 ¼ SMAD family member 1; p-Smad1/5/9 ¼ phospho-SMAD family member 1/5/9; BMP2 ¼ bone morphogenetic protein 2; BMPR2 ¼ bone morphogenetic protein receptor 2; GAPDH ¼ glyceraldehyde-3-phosphate dehydrogenase. CON, the offspring embryos of breeder hens fed with a normal diet; L-MLF, the offspring embryos of breeder hens fed a basal diet supplemented with 30 mg/kg MLF; H-MLF, the offspring embryos of breeder hens fed a basal diet supplemented with 60 mg/kg MLF. a,bDifferent letter represents statistically significant differences among the groups (P < 0.05).

Article Snippet: After washing 4 times with TBST buffer, the membraneswere incubated overnight at 4 Cwith the following primary antibodies respectively: SMAD family member 1 (Smad1), phospho-SMAD family member 1/5/9 (p-Smad1/5/9) (AF6451 and AF8313; Affinity Biosciences, USA); phospho-mitogen-activated protein kinase (p-MAPK), myogenic factor 5 (Myf5), myostatin (MSTN), mTOR, phosphorylated mammalian target of rapamycin (p-mTOR), BMP2, bone morphogenetic protein receptor 2 (BMPR2) (AP1165, A16227, A6913, A2445, AP0094, A0231 and A5666; ABclonal Technology, Wuhan, China); and MAPK (8690S, Cell Signaling Technology, Boston, USA).

Techniques: Expressing, Quantitative Proteomics, Western Blot, Cell Characterization

Fig. 3. Effects of maternal mulberry-leaf flavonoids (MLF) supplementation on the skeletal muscle development of chicken offspring at 1 d post-hatch. (A) The representative images of hematoxylin and eosin (H&E) staining on the breast muscle. Scale bar ¼ 20 mm. (B) The number of muscle fibres per unit area in the chicken offspring at 1 d after hatching. (C) Relative mRNA expression of genes related with myogenic regulatory factors, protein synthesis and degradation at 1 d after hatching (n ¼ 8). (D to H) Western blot analysis of p- MAPK, MAPK, p-mTOR, mTOR, Smad1, p-Smad1/5/9, BMP2, BMPR2, MSTN and Myf5 in the breast muscle (n ¼ 4). Myf5 ¼ myogenic factor 5; MyoG ¼ myogenin; MyoD ¼ myogenic differentiation antigen; Pax7 ¼ paired box protein pax-7; MSTN ¼ myostatin; IGF-1R ¼ insulin-like growth factor 1 receptor; mTOR ¼ mammalian target of rapamycin; MURF1 ¼ muscle RING finger 1; Atrogin-1 ¼ muscle atrophy f-box (MAFbx); MAPK ¼ mitogen-activated protein kinase; p-MAPK ¼ phospho-mitogen-activated protein kinase; p- mTOR ¼ phosphorylated mammalian target of rapamycin; Smad1 ¼ SMAD family member 1; p-Smad1/5/9 ¼ phospho-SMAD family member 1/5/9; BMP2 ¼ bone morphogenetic protein 2; BMPR2 ¼ bone morphogenetic protein receptor 2; GAPDH ¼ glyceraldehyde-3-phosphate dehydrogenase. CON, the chicken offspring of breeder hens fed with a normal diet; L-MLF, the chicken offspring of breeder hens fed a basal diet supplemented with 30 mg/kg MLF; H-MLF, the chicken offspring of breeder hens fed a basal diet supplemented with 60 mg/kg MLF. a,bDifferent letter represents statistically significant differences among the groups (P < 0.05).

Journal: Animal nutrition (Zhongguo xu mu shou yi xue hui)

Article Title: Maternal supplementation with mulberry-leaf flavonoids improves the development of skeletal muscle in the offspring of chickens.

doi: 10.1016/j.aninu.2024.04.005

Figure Lengend Snippet: Fig. 3. Effects of maternal mulberry-leaf flavonoids (MLF) supplementation on the skeletal muscle development of chicken offspring at 1 d post-hatch. (A) The representative images of hematoxylin and eosin (H&E) staining on the breast muscle. Scale bar ¼ 20 mm. (B) The number of muscle fibres per unit area in the chicken offspring at 1 d after hatching. (C) Relative mRNA expression of genes related with myogenic regulatory factors, protein synthesis and degradation at 1 d after hatching (n ¼ 8). (D to H) Western blot analysis of p- MAPK, MAPK, p-mTOR, mTOR, Smad1, p-Smad1/5/9, BMP2, BMPR2, MSTN and Myf5 in the breast muscle (n ¼ 4). Myf5 ¼ myogenic factor 5; MyoG ¼ myogenin; MyoD ¼ myogenic differentiation antigen; Pax7 ¼ paired box protein pax-7; MSTN ¼ myostatin; IGF-1R ¼ insulin-like growth factor 1 receptor; mTOR ¼ mammalian target of rapamycin; MURF1 ¼ muscle RING finger 1; Atrogin-1 ¼ muscle atrophy f-box (MAFbx); MAPK ¼ mitogen-activated protein kinase; p-MAPK ¼ phospho-mitogen-activated protein kinase; p- mTOR ¼ phosphorylated mammalian target of rapamycin; Smad1 ¼ SMAD family member 1; p-Smad1/5/9 ¼ phospho-SMAD family member 1/5/9; BMP2 ¼ bone morphogenetic protein 2; BMPR2 ¼ bone morphogenetic protein receptor 2; GAPDH ¼ glyceraldehyde-3-phosphate dehydrogenase. CON, the chicken offspring of breeder hens fed with a normal diet; L-MLF, the chicken offspring of breeder hens fed a basal diet supplemented with 30 mg/kg MLF; H-MLF, the chicken offspring of breeder hens fed a basal diet supplemented with 60 mg/kg MLF. a,bDifferent letter represents statistically significant differences among the groups (P < 0.05).

Article Snippet: After washing 4 times with TBST buffer, the membraneswere incubated overnight at 4 Cwith the following primary antibodies respectively: SMAD family member 1 (Smad1), phospho-SMAD family member 1/5/9 (p-Smad1/5/9) (AF6451 and AF8313; Affinity Biosciences, USA); phospho-mitogen-activated protein kinase (p-MAPK), myogenic factor 5 (Myf5), myostatin (MSTN), mTOR, phosphorylated mammalian target of rapamycin (p-mTOR), BMP2, bone morphogenetic protein receptor 2 (BMPR2) (AP1165, A16227, A6913, A2445, AP0094, A0231 and A5666; ABclonal Technology, Wuhan, China); and MAPK (8690S, Cell Signaling Technology, Boston, USA).

Techniques: Staining, Expressing, Western Blot, Cell Characterization

Fig. 4. Effects of maternal mulberry-leaf flavonoids (MLF) supplementation on the skeletal muscle development of chicken offspring on 14 d post-hatch. (A) The representative images of hematoxylin and eosin (H&E) staining on the breast muscle. Scale bar ¼ 20 mm. (B) The cross-sectional area in the chicken offspring at 14 d after hatching. (C) Relative mRNA expression of genes related with myogenic regulatory factors, protein synthesis and degradation at 14 d after hatching (n ¼ 8). (D to H) Western blot analysis of p-MAPK, MAPK, p-mTOR, mTOR, Smad1, p-Smad1/5/9, BMP2, BMPR2, MSTN and Myf5 in the breast muscle (n ¼ 4). Myf5 ¼ myogenic factor 5; MyoG ¼ myogenin; MyoD ¼ myogenic differentiation antigen; Pax7 ¼ paired box protein pax-7; MSTN ¼ myostatin; IGF-1R ¼ insulin-like growth factor 1 receptor; mTOR ¼ mammalian target of rapamycin; MURF1 ¼ muscle RING finger 1; Atrogin-1 ¼ muscle atrophy f-box (MAFbx); MAPK ¼ mitogen-activated protein kinase; p-MAPK ¼ phospho-mitogen-activated protein kinase; p- mTOR ¼ phosphorylated mammalian target of rapamycin; Smad1 ¼ SMAD family member 1; p-Smad1/5/9 ¼ phospho-SMAD family member 1/5/9; BMP2 ¼ bone morphogenetic protein 2; BMPR2 ¼ bone morphogenetic protein receptor 2; GAPDH ¼ glyceraldehyde-3-phosphate dehydrogenase. CON, the chicken offspring of breeder hens fed with a normal diet; L-MLF, the chicken offspring of breeder hens fed a basal diet supplemented with 30 mg/kg MLF; H-MLF, the chicken offspring of breeder hens fed a basal diet supplemented with 60 mg/kg MLF. a,bDifferent letter represents statistically significant differences among the groups (P < 0.05).

Journal: Animal nutrition (Zhongguo xu mu shou yi xue hui)

Article Title: Maternal supplementation with mulberry-leaf flavonoids improves the development of skeletal muscle in the offspring of chickens.

doi: 10.1016/j.aninu.2024.04.005

Figure Lengend Snippet: Fig. 4. Effects of maternal mulberry-leaf flavonoids (MLF) supplementation on the skeletal muscle development of chicken offspring on 14 d post-hatch. (A) The representative images of hematoxylin and eosin (H&E) staining on the breast muscle. Scale bar ¼ 20 mm. (B) The cross-sectional area in the chicken offspring at 14 d after hatching. (C) Relative mRNA expression of genes related with myogenic regulatory factors, protein synthesis and degradation at 14 d after hatching (n ¼ 8). (D to H) Western blot analysis of p-MAPK, MAPK, p-mTOR, mTOR, Smad1, p-Smad1/5/9, BMP2, BMPR2, MSTN and Myf5 in the breast muscle (n ¼ 4). Myf5 ¼ myogenic factor 5; MyoG ¼ myogenin; MyoD ¼ myogenic differentiation antigen; Pax7 ¼ paired box protein pax-7; MSTN ¼ myostatin; IGF-1R ¼ insulin-like growth factor 1 receptor; mTOR ¼ mammalian target of rapamycin; MURF1 ¼ muscle RING finger 1; Atrogin-1 ¼ muscle atrophy f-box (MAFbx); MAPK ¼ mitogen-activated protein kinase; p-MAPK ¼ phospho-mitogen-activated protein kinase; p- mTOR ¼ phosphorylated mammalian target of rapamycin; Smad1 ¼ SMAD family member 1; p-Smad1/5/9 ¼ phospho-SMAD family member 1/5/9; BMP2 ¼ bone morphogenetic protein 2; BMPR2 ¼ bone morphogenetic protein receptor 2; GAPDH ¼ glyceraldehyde-3-phosphate dehydrogenase. CON, the chicken offspring of breeder hens fed with a normal diet; L-MLF, the chicken offspring of breeder hens fed a basal diet supplemented with 30 mg/kg MLF; H-MLF, the chicken offspring of breeder hens fed a basal diet supplemented with 60 mg/kg MLF. a,bDifferent letter represents statistically significant differences among the groups (P < 0.05).

Article Snippet: After washing 4 times with TBST buffer, the membraneswere incubated overnight at 4 Cwith the following primary antibodies respectively: SMAD family member 1 (Smad1), phospho-SMAD family member 1/5/9 (p-Smad1/5/9) (AF6451 and AF8313; Affinity Biosciences, USA); phospho-mitogen-activated protein kinase (p-MAPK), myogenic factor 5 (Myf5), myostatin (MSTN), mTOR, phosphorylated mammalian target of rapamycin (p-mTOR), BMP2, bone morphogenetic protein receptor 2 (BMPR2) (AP1165, A16227, A6913, A2445, AP0094, A0231 and A5666; ABclonal Technology, Wuhan, China); and MAPK (8690S, Cell Signaling Technology, Boston, USA).

Techniques: Staining, Expressing, Western Blot, Cell Characterization

Calcitriol inhibits PASMC proliferation via BMPR2. Human control PASMC were transfected with siRNA for BMPR2 (siBMPR2) or control siRNA (scramble). ( A ) BMPR2 mRNA expression assessed by qRT-PCR after 48 h post-transfection. Data is expressed as scatter plots and bars with medians, * p < 0.05, Mann–Whitney test. ( B ) Effects of calcitriol on proliferation in silenced BMPR2 PASMC measured by MTT assay. Results are expressed as mean ± SEM. *p < 0.05, t-test vs scramble. ( C ) and ( D ) Effects of calcitriol (1–100 nmol/l) on proliferation in PASMC transfected with siBMPR2 or scramble, measured by MTT and BrdU assays, respectively. * p < 0.05, two-way ANOVA, Bonferroni post hoc test, vs scramble. ( E ) Effects of calcitriol on proliferation in PASMC in the presence or absence of DMH1 (5 µmol/l), by MTT and BrdU assay; *** p < 0.001 calcitriol vs vehicle (black column), two way-ANOVA. n = 4–5 different cultures in duplicate or triplicate.

Journal: Scientific Reports

Article Title: Vitamin D receptor and its antiproliferative effect in human pulmonary arterial hypertension

doi: 10.1038/s41598-024-78380-9

Figure Lengend Snippet: Calcitriol inhibits PASMC proliferation via BMPR2. Human control PASMC were transfected with siRNA for BMPR2 (siBMPR2) or control siRNA (scramble). ( A ) BMPR2 mRNA expression assessed by qRT-PCR after 48 h post-transfection. Data is expressed as scatter plots and bars with medians, * p < 0.05, Mann–Whitney test. ( B ) Effects of calcitriol on proliferation in silenced BMPR2 PASMC measured by MTT assay. Results are expressed as mean ± SEM. *p < 0.05, t-test vs scramble. ( C ) and ( D ) Effects of calcitriol (1–100 nmol/l) on proliferation in PASMC transfected with siBMPR2 or scramble, measured by MTT and BrdU assays, respectively. * p < 0.05, two-way ANOVA, Bonferroni post hoc test, vs scramble. ( E ) Effects of calcitriol on proliferation in PASMC in the presence or absence of DMH1 (5 µmol/l), by MTT and BrdU assay; *** p < 0.001 calcitriol vs vehicle (black column), two way-ANOVA. n = 4–5 different cultures in duplicate or triplicate.

Article Snippet: Human control PASMC were transfected with specific siRNA against BMPR2 (SR300456B, OriGene, Maryland, USA), KCNK3 (gene encoding TASK-1, SASI_Hs01_00108786, Sigma-Aldrich, St. Louis, USA), BIRC5 ( gene encoding survivin, SASI_Hs01_00052229, Sigma-Aldrich, St. Louis, USA), and control non-targeting siRNA (SIC001 scramble siRNA, Sigma-Aldrich, St. Louis, USA), using LipofectamineTM RNAiMAX (Thermo Fisher Scientific, Massachusetts, USA) according to the manufacturer’s instructions as previously reported .

Techniques: Control, Transfection, Expressing, Quantitative RT-PCR, MANN-WHITNEY, MTT Assay, BrdU Staining

Structural details of inhibitor binding to SMURF1, conservation of lysine residues on α helix #1, and AlphaFold model of the SMURF1:BMPR2 complex, related to , , , and (A) Crystallography parameters. ∗ The highest resolution shell is shown in parenthesis. (B) Surface representation of SMURF1 shows that the inhibitor is minimally exposed. (C) Detailed structural insight into the SMURF1—inhibitor complex, with a zoomed view of the binding cavity from three different angles. (D) 2D representation of the inhibitor binding site, rendered using LigPlot+ v.2.2 https://www.ebi.ac.uk/thornton-srv/software/LigPlus/ . (E) mFo-DFc simulated-annealing electron density omit map showing the α10 and the hinge region without (left) and with (right) the inhibitor. The map was calculated by omitting the entire model of the α 10, the hinge, and the inhibitor using simulated-annealing sigma A analysis contoured at 2.75 (SMURF1, apo) and 2.05 Å (SMURF1, Cpd-8) at 3σ. (F) Structures of HECT ligase showing conservation of lysine residues on α helix #1. Superimposing the structures of Rsp5 (3OLM), NEDD4 (2XBB), and SMURF1 and AlphaFold model of E6AP/UBE3A HECT domains shows the conservation of lysine (K) residues on α helix #1, previously demonstrated to undergo self-ubiquitylation that downregulates the ligase activity. (G) AlphaFold model of the SMURF1:BMPR2 complex. The sequences of full-length SMURF1 and the intracellular domain of BMPR2 were modeled in AlphaFold3. The domains of SMURF1 are indicated. Residues predicted to participate in binding are shown as ball-and-sticks. The model suggests that WW1 and WW2 domains directly interact with the kinase domain of BMPR2.

Journal: Cell

Article Title: Therapeutic potential of allosteric HECT E3 ligase inhibition

doi: 10.1016/j.cell.2025.03.001

Figure Lengend Snippet: Structural details of inhibitor binding to SMURF1, conservation of lysine residues on α helix #1, and AlphaFold model of the SMURF1:BMPR2 complex, related to , , , and (A) Crystallography parameters. ∗ The highest resolution shell is shown in parenthesis. (B) Surface representation of SMURF1 shows that the inhibitor is minimally exposed. (C) Detailed structural insight into the SMURF1—inhibitor complex, with a zoomed view of the binding cavity from three different angles. (D) 2D representation of the inhibitor binding site, rendered using LigPlot+ v.2.2 https://www.ebi.ac.uk/thornton-srv/software/LigPlus/ . (E) mFo-DFc simulated-annealing electron density omit map showing the α10 and the hinge region without (left) and with (right) the inhibitor. The map was calculated by omitting the entire model of the α 10, the hinge, and the inhibitor using simulated-annealing sigma A analysis contoured at 2.75 (SMURF1, apo) and 2.05 Å (SMURF1, Cpd-8) at 3σ. (F) Structures of HECT ligase showing conservation of lysine residues on α helix #1. Superimposing the structures of Rsp5 (3OLM), NEDD4 (2XBB), and SMURF1 and AlphaFold model of E6AP/UBE3A HECT domains shows the conservation of lysine (K) residues on α helix #1, previously demonstrated to undergo self-ubiquitylation that downregulates the ligase activity. (G) AlphaFold model of the SMURF1:BMPR2 complex. The sequences of full-length SMURF1 and the intracellular domain of BMPR2 were modeled in AlphaFold3. The domains of SMURF1 are indicated. Residues predicted to participate in binding are shown as ball-and-sticks. The model suggests that WW1 and WW2 domains directly interact with the kinase domain of BMPR2.

Article Snippet: The following primary antibodies were used and paired with appropriate secondary antibodies for detection: SMURF1 (H00057154-M01, Abnova, USA and H60, Sant Cruz Biotechnology, USA), BMPR2 (orb69398, Biorbyt, UK and BD, #612292), anti-myc (sc-40, Sant Cruz Biotechnology, USA), SMAD1/5/9 (ab66737, Abcam, USA), phospho-SMAD1/5 (9516S, Cell Signaling Technology, USA), ID1 (M085, CalBioreagents, USA), GAPDH (2118L, Cell signaling Technology, USA), Fla-Tag (FG4R, Thermo Fisher Scientific, MA1-91878), Pan Actin (4968S, Cell Signaling) and beta-actin (4967, Cell Signaling Technology, USA).

Techniques: Binding Assay, Software, Activity Assay

SMURF1 inhibitors restore BMP signaling and pulmonary vascular cell homeostasis (A) Scheme of SMURF1-BMPR2 and SMAD1 split-CAT based E. coli selection system, showing target ubiquitylation resulting in CAT assembly, resistance, and selective growth. (B and C) Hyperactive K381R (black) increases and catalytically inactive C725A (red) reduces SMURF1-dependent direct target ubiquitylation of SMAD1 (B) and BMPR2 (C) (inset represents area-under-the-curve of relative growth; n = 3, ∗∗ p < 0.01, ∗∗∗ p < 0.001, one-way ANOVA with Dunnett’s correction). (D) Representative western blot demonstrating stabilization of overexpressed SMAD1 in HEK cells in the presence of SMURF1 inhibitor. Mutations that reduce the flexibility (G634P) and length (Δ637 KID ) of the hinge result in reduce SMURF1 activity. Mutations that preserve the flexibility (G633C, D636G [GGLD]) and length (637GGLD INS ) of the SMURF1 glycine hinge escape the effect of the inhibitor. (E) Representative western blot demonstrating stabilization of overexpressed BMPR2-myc in HEK cells in the presence of SMURF1 inhibitor. (F) Immunoblotting of BMPR2, SMURF1, SMAD1/5/8, phosphorylated SMAD1/5/8, ID1, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in PASMC cultured without or with BMP4 and SMURF1 inhibitor (Cpd-6) ( n = 9 separate experiments across cells from 3 PAH donor lungs, mean ± SEM). (G and H) Quantification of apoptosis in PAECs. (G) Representative time curve ( n = 5 technical replicates, mean ± SD) and (H) group data at 300 min with Cpd-6 or vehicle ( n = 6 separate donors, mean ± SEM). (I and J) Quantification of proliferation: (I) representative time course ( n = 5 technical replicates, mean ± SD) in PAEC with cell confluence mask for each dose of Cpd-6 or vehicle (orange) and (J) group data ( n = 3 separate PAEC donors; mean ± SEM). (K) Migration of PASMCs with Cpd-6 or vehicle measured via disc closure assay ( n = 2–3 separate donors). (L) Representative time course plots showing proliferation of PASMC from an idiopathic PAH patient with Cpd-6 or vehicle with cell confluence mask for each dose (orange) ( n = 5 technical replicates per concentration from one idiopathic PAH donor line, mean ± SD). (M) Group proliferation data at 72 h in PASMCs from patients with idiopathic or hereditary PAH ( n = 4–5 separate donor lines, mean ± SEM). ∗ p < 0.05, ∗∗ p < 0.01, one-way ANOVA with Dunnett’s correction. See also , , and .

Journal: Cell

Article Title: Therapeutic potential of allosteric HECT E3 ligase inhibition

doi: 10.1016/j.cell.2025.03.001

Figure Lengend Snippet: SMURF1 inhibitors restore BMP signaling and pulmonary vascular cell homeostasis (A) Scheme of SMURF1-BMPR2 and SMAD1 split-CAT based E. coli selection system, showing target ubiquitylation resulting in CAT assembly, resistance, and selective growth. (B and C) Hyperactive K381R (black) increases and catalytically inactive C725A (red) reduces SMURF1-dependent direct target ubiquitylation of SMAD1 (B) and BMPR2 (C) (inset represents area-under-the-curve of relative growth; n = 3, ∗∗ p < 0.01, ∗∗∗ p < 0.001, one-way ANOVA with Dunnett’s correction). (D) Representative western blot demonstrating stabilization of overexpressed SMAD1 in HEK cells in the presence of SMURF1 inhibitor. Mutations that reduce the flexibility (G634P) and length (Δ637 KID ) of the hinge result in reduce SMURF1 activity. Mutations that preserve the flexibility (G633C, D636G [GGLD]) and length (637GGLD INS ) of the SMURF1 glycine hinge escape the effect of the inhibitor. (E) Representative western blot demonstrating stabilization of overexpressed BMPR2-myc in HEK cells in the presence of SMURF1 inhibitor. (F) Immunoblotting of BMPR2, SMURF1, SMAD1/5/8, phosphorylated SMAD1/5/8, ID1, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in PASMC cultured without or with BMP4 and SMURF1 inhibitor (Cpd-6) ( n = 9 separate experiments across cells from 3 PAH donor lungs, mean ± SEM). (G and H) Quantification of apoptosis in PAECs. (G) Representative time curve ( n = 5 technical replicates, mean ± SD) and (H) group data at 300 min with Cpd-6 or vehicle ( n = 6 separate donors, mean ± SEM). (I and J) Quantification of proliferation: (I) representative time course ( n = 5 technical replicates, mean ± SD) in PAEC with cell confluence mask for each dose of Cpd-6 or vehicle (orange) and (J) group data ( n = 3 separate PAEC donors; mean ± SEM). (K) Migration of PASMCs with Cpd-6 or vehicle measured via disc closure assay ( n = 2–3 separate donors). (L) Representative time course plots showing proliferation of PASMC from an idiopathic PAH patient with Cpd-6 or vehicle with cell confluence mask for each dose (orange) ( n = 5 technical replicates per concentration from one idiopathic PAH donor line, mean ± SD). (M) Group proliferation data at 72 h in PASMCs from patients with idiopathic or hereditary PAH ( n = 4–5 separate donor lines, mean ± SEM). ∗ p < 0.05, ∗∗ p < 0.01, one-way ANOVA with Dunnett’s correction. See also , , and .

Article Snippet: The following primary antibodies were used and paired with appropriate secondary antibodies for detection: SMURF1 (H00057154-M01, Abnova, USA and H60, Sant Cruz Biotechnology, USA), BMPR2 (orb69398, Biorbyt, UK and BD, #612292), anti-myc (sc-40, Sant Cruz Biotechnology, USA), SMAD1/5/9 (ab66737, Abcam, USA), phospho-SMAD1/5 (9516S, Cell Signaling Technology, USA), ID1 (M085, CalBioreagents, USA), GAPDH (2118L, Cell signaling Technology, USA), Fla-Tag (FG4R, Thermo Fisher Scientific, MA1-91878), Pan Actin (4968S, Cell Signaling) and beta-actin (4967, Cell Signaling Technology, USA).

Techniques: Selection, Western Blot, Activity Assay, Cell Culture, Migration, Concentration Assay

SMURF1 expression in PAH (A) Schematic representation of canonical BMP signaling resulting in SMAD1/5/8 phosphorylation, in nuclear translocation of SMAD4 and ID1 expression, and its negative regulation by SMURF1-mediated ubiquitylation and degradation of BMPR2 and SMAD1/5/8. (B) In HEK293 cells stably transfected with GFP-tagged SMURF1, BMP4 stimulation results in a decrease in GFP signal and short interfering RNA (siRNA) knockdown of ACVRL1, BMPR2, Endoglin (ENG), or SMAD9, and BMP4 stimulation results in increased GFP signal. n = 3 separate experiments; presented as mean ± SEM. ∗ p < 0.05, ∗∗ p < 0.01, relative to untreated, unpaired Student's t test. (C) Expression of SMURF1 is increased in PASMC from patients with idiopathic and heritable PAH when compared with PASMC from patients without PAH. n = 6 PAH donor lines and n = 9 control lines; presented as mean ± SEM. ∗∗ p < 0.01, unpaired Student's t test. (D) SMURF1 expression in the pulmonary artery intima and media in patients with PAH. SMURF1 (purple) protein co-localization with an endothelial (von Willebrand factor [vWF], yellow) or smooth muscle marker (Alpha Smooth Muscle Actin [αSMA], yellow) is indicated by a red/brown color shift. Representative images were obtained from 19 controls and 33 patients with PAH. Scale bar, 60 μm. Arrows indicate areas of co-localization. See also .

Journal: Cell

Article Title: Therapeutic potential of allosteric HECT E3 ligase inhibition

doi: 10.1016/j.cell.2025.03.001

Figure Lengend Snippet: SMURF1 expression in PAH (A) Schematic representation of canonical BMP signaling resulting in SMAD1/5/8 phosphorylation, in nuclear translocation of SMAD4 and ID1 expression, and its negative regulation by SMURF1-mediated ubiquitylation and degradation of BMPR2 and SMAD1/5/8. (B) In HEK293 cells stably transfected with GFP-tagged SMURF1, BMP4 stimulation results in a decrease in GFP signal and short interfering RNA (siRNA) knockdown of ACVRL1, BMPR2, Endoglin (ENG), or SMAD9, and BMP4 stimulation results in increased GFP signal. n = 3 separate experiments; presented as mean ± SEM. ∗ p < 0.05, ∗∗ p < 0.01, relative to untreated, unpaired Student's t test. (C) Expression of SMURF1 is increased in PASMC from patients with idiopathic and heritable PAH when compared with PASMC from patients without PAH. n = 6 PAH donor lines and n = 9 control lines; presented as mean ± SEM. ∗∗ p < 0.01, unpaired Student's t test. (D) SMURF1 expression in the pulmonary artery intima and media in patients with PAH. SMURF1 (purple) protein co-localization with an endothelial (von Willebrand factor [vWF], yellow) or smooth muscle marker (Alpha Smooth Muscle Actin [αSMA], yellow) is indicated by a red/brown color shift. Representative images were obtained from 19 controls and 33 patients with PAH. Scale bar, 60 μm. Arrows indicate areas of co-localization. See also .

Article Snippet: The following primary antibodies were used and paired with appropriate secondary antibodies for detection: SMURF1 (H00057154-M01, Abnova, USA and H60, Sant Cruz Biotechnology, USA), BMPR2 (orb69398, Biorbyt, UK and BD, #612292), anti-myc (sc-40, Sant Cruz Biotechnology, USA), SMAD1/5/9 (ab66737, Abcam, USA), phospho-SMAD1/5 (9516S, Cell Signaling Technology, USA), ID1 (M085, CalBioreagents, USA), GAPDH (2118L, Cell signaling Technology, USA), Fla-Tag (FG4R, Thermo Fisher Scientific, MA1-91878), Pan Actin (4968S, Cell Signaling) and beta-actin (4967, Cell Signaling Technology, USA).

Techniques: Expressing, Phospho-proteomics, Translocation Assay, Stable Transfection, Transfection, Small Interfering RNA, Knockdown, Control, Marker

BMP signaling and proteomic effects of SMURF1 inhibition in mammalian cells, related to (A) Comparison of small-molecule SMURF1 inhibition and siRNA-mediated SMURF1 knockdown on BMP signaling (BMP response element – ID1 promoter activation) in HEK293 cells. (B–D) Summary of expression proteomics experiments comparing PASMCs treated under hypoxic conditions ±BMP4 or ±SMURF1 inhibitor Cpd-6 (SMURF1i). (B) Experimental workflow. Table: sample conditions for PASMC BMPR2 (C347Y) mutant cells undergoing TMT quantitative proteomics profiling at 24 h. (C) Log 2 ratios of protein abundances for treated versus control (DMSO) in selected conditions. Data represent two biological replicates ( n = 2) per treatment condition in a single experiment derived from individual donors. Highlighted proteins correspond to “IL-1 beta- and endothelin-1-induced fibroblast/myofibroblast migration and extracellular matrix production in asthmatic airways” gene set, which was significantly enriched among dysregulated proteins, only in condition (B) (ii). Inserts show heatmap for ratios for donors 1 and 2 for proteins highlighted in the plot. (D) Log 2 ratio of known SMURF1 targets RhoA and TGFBR1 detected in proteomic study and chemiluminescence of SMURF1, BMPR2, SMAD1, pSMAD1, and ID1 in samples used for proteomic studies measured by western (not detected by proteomics). (E) Summary of significantly enriched terms for mutant cells under hypoxic conditions pre-treated with BMP4, followed by treatment with SMURF1 inhibitor or DMSO.

Journal: Cell

Article Title: Therapeutic potential of allosteric HECT E3 ligase inhibition

doi: 10.1016/j.cell.2025.03.001

Figure Lengend Snippet: BMP signaling and proteomic effects of SMURF1 inhibition in mammalian cells, related to (A) Comparison of small-molecule SMURF1 inhibition and siRNA-mediated SMURF1 knockdown on BMP signaling (BMP response element – ID1 promoter activation) in HEK293 cells. (B–D) Summary of expression proteomics experiments comparing PASMCs treated under hypoxic conditions ±BMP4 or ±SMURF1 inhibitor Cpd-6 (SMURF1i). (B) Experimental workflow. Table: sample conditions for PASMC BMPR2 (C347Y) mutant cells undergoing TMT quantitative proteomics profiling at 24 h. (C) Log 2 ratios of protein abundances for treated versus control (DMSO) in selected conditions. Data represent two biological replicates ( n = 2) per treatment condition in a single experiment derived from individual donors. Highlighted proteins correspond to “IL-1 beta- and endothelin-1-induced fibroblast/myofibroblast migration and extracellular matrix production in asthmatic airways” gene set, which was significantly enriched among dysregulated proteins, only in condition (B) (ii). Inserts show heatmap for ratios for donors 1 and 2 for proteins highlighted in the plot. (D) Log 2 ratio of known SMURF1 targets RhoA and TGFBR1 detected in proteomic study and chemiluminescence of SMURF1, BMPR2, SMAD1, pSMAD1, and ID1 in samples used for proteomic studies measured by western (not detected by proteomics). (E) Summary of significantly enriched terms for mutant cells under hypoxic conditions pre-treated with BMP4, followed by treatment with SMURF1 inhibitor or DMSO.

Article Snippet: The following primary antibodies were used and paired with appropriate secondary antibodies for detection: SMURF1 (H00057154-M01, Abnova, USA and H60, Sant Cruz Biotechnology, USA), BMPR2 (orb69398, Biorbyt, UK and BD, #612292), anti-myc (sc-40, Sant Cruz Biotechnology, USA), SMAD1/5/9 (ab66737, Abcam, USA), phospho-SMAD1/5 (9516S, Cell Signaling Technology, USA), ID1 (M085, CalBioreagents, USA), GAPDH (2118L, Cell signaling Technology, USA), Fla-Tag (FG4R, Thermo Fisher Scientific, MA1-91878), Pan Actin (4968S, Cell Signaling) and beta-actin (4967, Cell Signaling Technology, USA).

Techniques: Inhibition, Comparison, Knockdown, Activation Assay, Expressing, Mutagenesis, Quantitative Proteomics, Control, Derivative Assay, Migration, Western Blot

FIGURE 3 | Urine proteins that correlate best with urine creatinine. The aptamer-based screen identified five urine proteins that correlated best with urine creatinine but not differ between subject groups. As described in Figure 1, the levels of 1129 urine proteins were assayed in 7 active LN, 8 inactive LN, 8 healthy controls using an aptamer-based proteomic screen. Of these, urine BMPRII, Dectin-1, HVEM, RELT, and SPINT2 (A–E) exhibited the highest Pearson R correlation with creatinine but did not differ significantly between the subject groups.

Journal: Frontiers in immunology

Article Title: Comprehensive Urinomic Identification of Protein Alternatives to Creatinine Normalization for Diagnostic Assessment of Lupus Nephritis.

doi: 10.3389/fimmu.2022.853778

Figure Lengend Snippet: FIGURE 3 | Urine proteins that correlate best with urine creatinine. The aptamer-based screen identified five urine proteins that correlated best with urine creatinine but not differ between subject groups. As described in Figure 1, the levels of 1129 urine proteins were assayed in 7 active LN, 8 inactive LN, 8 healthy controls using an aptamer-based proteomic screen. Of these, urine BMPRII, Dectin-1, HVEM, RELT, and SPINT2 (A–E) exhibited the highest Pearson R correlation with creatinine but did not differ significantly between the subject groups.

Article Snippet: Kits were purchased for HVEM (Cat. No. EK1226, Boster Biological Technology, Pleasanton, CA, USA), BMPRII (Cat. No. ELH-BMPR2-1, RayBiotech, Inc., Norcross, GA, USA), Dectin-1 (Cat. No. ELH-DECTIN1-1, RayBiotech, Inc., Norcross, GA, USA), SPINT2 (Cat. No. DY1106, R&D Systems, Inc., Minneapolis, MN, USA), and RELT (Cat. No. SEK10530, Sino Biological Inc., Beijing, China).

Techniques: